Efficacy of imatinib in an extra-gastrointestinal stromal tumor presenting as a unilateral ovarian mass

8^th Euro Global Summit on Cancer Therapy

November 03-05, 2015 Valencia, Spain

Ann Meredith U Garcia, John Timojin R Tawasil and Dennis L Sacdalan

University of the Philippines, Philippines

Scientific Tracks Abstracts: J Cancer Sci Ther

Abstract :

We present the case of a 58-year-old female with a 6-month history of abdominal enlargement. She had previous bowel surgery for an undocumented diagnosis 20 years prior. CT scan showed a pelvic mass. Intraoperatively, the right adnexa was converted into a large, encapsulated, cystic mass with areas of necrosis and hemorrhage. Adherent segments of the ileum and omentum were resected with no masses or gross tumor implants. Histopathologic diagnosis was low-grade fibrosarcoma of the right ovary, with both ileum and omentum positive for tumor. Immunostaining with CD117 (+) and S-100 (-) were done. Subsequent work-up showed hepatic nodules. A diagnosis of gastrointestinal stromal tumor (GIST) was made and imatinib mesylate was started with good clinical response. Preoperative diagnosis of GISTs is uncommon due to its rarity and varied manifestations, more so if it presents as an ovarian mass, an extremely rare event. Routine imaging studies cannot differentiate extra-gastrointestinal stromal tumors (eGISTs) from ovarian cancer, so the diagnosis rests on histology and immunohistochemistry. The significance of the patient�s previous intestinal pathology in relation to the present tumor cannot be reliably discerned, but the treatment is similar for both recurrent and metastatic cases, whether this is a primary ileal or ovarian GIST. Surgery is the mainstay of treatment and correct postoperative diagnosis is crucial as misdiagnosis carries significant therapeutic and prognostic implications because of the ineffectiveness of standard chemotherapy and radiotherapy. The oral tyrosine kinase inhibitor, imatinib mesylate, has been demonstrated to be an effective treatment for both GISTs and eGISTs.

Biography :

Ann Meredith U Garcia completed her MD from the University of the Philippines College of Medicine. She underwent Internal Medicine residency training at the University of the Philippines – Philippine General Hospital and is currently a second-year Medical Oncology fellow-in-training at the same institution. She is also currentlty pursuing Master of Clinical Medicine (Major in Medical Oncology) degree at the University of the Philippines – Manila National Graduate Office for the Health Sciences.

Email: meredith_xxi@yahoo.com